Business Context and Reporting Period
This Form 8-K Current Report from Senti Biosciences Holdings, Inc. (SNTI) covers events occurring on January 31, 2025, and February 5, 2025. The filing addresses a change in the Company's executive leadership structure regarding its principal financial and accounting officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Interim CFO: On January 31, 2025, the consulting agreement for Yvonne Li, the Company's Interim Chief Financial Officer, expired. Effective that date, Ms. Li ceased serving as the Company's principal financial officer and principal accounting officer.
- Transition Arrangement: On February 5, 2025, the Company entered into a new consulting agreement with Ms. Li. She will serve as a consultant to facilitate an orderly transition of her responsibilities until March 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors beyond the operational transition of financial leadership. The full text of the New Consulting Agreement is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2025.
Investor Verification Checklist
- Verify the appointment of a permanent Chief Financial Officer to replace the interim role.
- Review the upcoming Form 10-Q for the full terms of the new consulting agreement with Yvonne Li.
- Monitor for any delays in financial reporting or audit processes during the transition period ending March 31, 2025.